Brighton Jones’s Allogene Therapeutics ALLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.4K Sell
13,357
-19,645
-60% -$37.4K ﹤0.01% 1379
2026
Q2
$68.6K Sell
33,002
-1,450
-4% -$3.18K ﹤0.01% 1340
2026
Q1
$84.1K Buy
+34,452
New +$69.1K ﹤0.01% 1138
2025
Q4
– Sell
-25,168
Closed -$31.2K – 90
2025
Q3
$31.2K Buy
25,168
+11,311
+82% +$13.5K ﹤0.01% 1015
2025
Q2
$15.7K Buy
13,857
+945
+7% +$1.26K ﹤0.01% 921
2025
Q1
$18.9K Buy
+12,912
New +$24.3K ﹤0.01% 695

Other funds holding ALLO

Brighton Jones's ALLO Position: Q3 2026 in Review

Brighton Jones reduced its Allogene Therapeutics (ALLO) stake by 60% in Q3 2026, selling an estimated $37.4K and leaving 13,357 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1379.

Brighton Jones first reported a position in ALLO in Q1 2025 and has held it in 6 quarters since. The position peaked at $84.1K in Q1 2026. 158 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Brighton Jones held 13,357 shares of Allogene Therapeutics worth $21.4K as of Q3 2026.
  • Brighton Jones sold 19,645 Allogene Therapeutics shares in Q3 2026, an estimated $37.4K.
  • Allogene Therapeutics made up ﹤0.01% of Brighton Jones's portfolio in Q3 2026, its #1379 holding.
  • Brighton Jones first reported a position in Allogene Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Brighton Jones's Allogene Therapeutics position peaked at $84.1K in Q1 2026.
  • 158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.